Abstract:An increasing interest in patient-specific disease modeling of neuropsychiatric disorders with multifactorial etiology has been witnessed by researchers worldwide [1]. Bipolar disorder (BD) is a complex neuropsychiatric disorder with high heritability rates that could benefit from the use of patient-specific cell lines to study molecular mechanisms [2]. We therefore read with interest the work of Hewitt and colleagues (2023), which investigated aspects of BD pathophysiology and more specifically calcium-related mechanisms, using induced pluripotent stem cells (iPSC)-derived neurons. However, we noted that some aspects of the study could be further clarified, which would facilitate the interpretation of these findings for the wider clinical and non-clinical scientific community interested in this field. For example, the absence of information regarding quality control (QC) in some of the generated iPSC lines, clinical details, repository information, and methodological details. The current study from Hewitt and colleagues (Suppl. Fig. S1 A) examined three patients and three controls (one clone each) [3]. However, it is concerning that neither the current study [3] nor the linked work by Zimmermann et al. [4] and Bavamian et al. [5] appeared to clearly provide and/or describe QC information for all the iPSCs that were produced [6]. Good Cell Culture Practices outlined by the International Society for Stem Cell Research highlights the need for structured iPSC generation and reporting, to enable information interchange and biological characterization of cell lines in a reproducible manner [7]. One of the international registries for pluripotent stem cells is the hPSCReg, which is free of charge and contains data about multiple cell lines generated by researchers around the world [8]. This possibility helps with the dissemination of trustworthy, reproducible information about newly generated iPSCs amongst the iPSC community. Using these cells for the examination of complex neuropsychiatric disorders is powerful, as the presence of numerous sporadic cases can be attributed to polygenic factors with individually small impact magnitudes, rather than solely to the impact of environmental factors or new mutations with larger effect sizes [9]. Therefore, it is crucial to thoroughly analyze clinical and polygenic data from the donors in order to assess the impact of environmental and genetic factors on the etiology of these disorders in sporadic cases [6]. Unfortunately, the article lacked the aforementioned data.

Need for high-resolution Genetic Analysis in iPSC: Results and Lessons from the ForIPS Consortium

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

A promising iPS-based single-cell cloning strategy revealing signatures of somatic mutations in heterogeneous normal cells.

Induced Pluripotent Stem Cells As a Disease Modeling and Drug Screening Platform

Genetic heterogeneity of induced pluripotent stem cells: results from 24 clones derived from a single C57BL/6 mouse

KOLF2.1J iPSCs carry CNVs associated with neurodevelopmental disorders

Large-Scale Profiling Reveals the Influence of Genetic Variation on Gene Expression in Human Induced Pluripotent Stem Cells

Derivation of Ipsc Lines from Three Young Healthy Donors of Caucasian Origin (Nuigi035-A; NUIGi036-A; NUIGi037-A).

Correspondence to "Bipolar disorder-iPSC derived neural progenitor cells exhibit dysregulation of store-operated Ca 2+ entry and accelerated differentiation" by Hewitt et al. (PMID: 37402854)

Drug screening for human genetic diseases using iPSC models

Reassessment of marker genes in human induced pluripotent stem cells for enhanced quality control

Scaled and Efficient Derivation of Loss of Function Alleles in Risk Genes for Neurodevelopmental and Psychiatric Disorders in Human iPSC

Identification of the New Gene Zrsr1 to Associate with the Pluripotency State in Induced Pluripotent Stem Cells (ipscs) Using High Throughput Sequencing Technology.

Scaled and efficient derivation of loss-of-function alleles in risk genes for neurodevelopmental and psychiatric disorders in human iPSCs

Generation and benchmarking of a collection of hiPSC lines from Schizophrenia Patients with Diverse Clinical Profiles

Genome-wide CNV Analysis in Mouse Induced Pluripotent Stem Cells Reveals Dosage Effect of Pluripotent Factors on Genome Integrity

Evaluation of the impact of iPSC differentiation protocols on transcriptomic signatures

Functional characterization of gene regulatory elements and neuropsychiatric disease-associated risk loci in iPSCs and iPSC-derived neurons

A Multistep Workflow to Evaluate Newly Generated iPSCs and Their Ability to Generate Different Cell Types

CRISPR single base editing, neuronal disease modelling and functional genomics for genetic variant analysis: pipeline validation using Kleefstra syndrome EHMT1 haploinsufficiency

Generation of induced pluripotent stem cell lines from two unrelated patients affected by intellectual disability carrying homozygous variants in SGIP1